Newsletter Tool

Today's Rundown

After Pfizer's pitch for 2nd round of COVID boosters, Moderna files a more ambitious FDA submission
Study: Value-based care lowers hospitalizations, ER visits in Medicare Advantage
Illumina sues Guardant Health, claiming founders stole cancer testing trade secrets
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts
Pharma’s ‘superhero’ image fades as inflation, Ukraine drown out the industry
A look at the most interesting innovations at SXSW 2022: From holograms to the future of psychedelics
As HAE offerings from Takeda and BioCryst gain steam, a doc survey offers lessons for the long term: analyst
Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trial
More than half of cancer patients end up with medical debt
Newly discovered Alzheimer's biomarkers may bring more equitable screening tests, Mayo Clinic finds
Summit says path forward for failed C. difficile drug is likely through partnerships
Amid sales slump, Teva CEO Schultz's pay falls 7% to $14.7M
NIH's All of Us project opens floodgates, releasing first 100K sequenced genomes to researchers
Drug designed to help alcoholics might be the key to treating progressive blindness
Pfizer CEO scored big raise—to $24M—as drugmaker played a leading role in pandemic fight

Featured Story

After Pfizer's pitch for 2nd round of COVID boosters, Moderna files a more ambitious FDA submission

By Kevin Dunleavy

Moderna has asked the FDA to authorize a second booster dose of its COVID-19 vaccine for all adults. The move comes on the heels of a similar request from Pfizer and BioNTech for authorization of a second booster shot of their vaccine for people 65 and older.

Study: Value-based care lowers hospitalizations, ER visits in Medicare Advantage

By Paige Minemyer

Value-based care can drive down acute care episodes such as hospitalizations and emergency room visits among Medicare Advantage beneficiaries, a new study shows.

Illumina sues Guardant Health, claiming founders stole cancer testing trade secrets

By Conor Hale

The litigation places Illumina in the tricky position of suing not only one of its own customers but a main competitor in the burgeoning liquid biopsy space following its acquisition of Grail.

Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts

By Kyle LaHucik

Protalix BioTherapeutics intends to resubmit its once-rejected Fabry disease drug to the FDA in the second half of this year thanks to new phase 3 data, with more on the way in the coming weeks, a company spokesperson told Fierce Biotech.

Pharma’s ‘superhero’ image fades as inflation, Ukraine drown out the industry

By Ben Adams

The pharmaceutical industry’s reputation was flying high during the first year of the pandemic, but its steady decline continues. Harris Poll finds pharma's image score is now down 15% from its peak in late 2020.

A look at the most interesting innovations at SXSW 2022: From holograms to the future of psychedelics

By Heather Landi

The 10-day SXSW conference and festival brings together the worlds of tech, music and film and there were cutting-edge health tech innovations to check out as well. Here are innovations in healthcare, tech and wellness that caught our eye at SXSW 2022.

As HAE offerings from Takeda and BioCryst gain steam, a doc survey offers lessons for the long term: analyst

By Angus Liu

Orladeyo, the first oral option to prevent hereditary angioedema attacks, has been on the market for over a year now. A survey shows the BioCryst Pharmaceuticals drug and Takeda’s rival injection Takhzyro are welcomed by doctors. But both drugs face long-term uncertainties, one analyst says.

Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trial

By Nick Paul Taylor

Onconova Therapeutics’ early-phase development program for the multikinase inhibitor narazaciclib has cleared a small milestone, with the lack of dose-limiting toxicities in solid tumor patients in the original cohorts emboldening the biotech to plan to file a protocol amendment to study higher doses.

More than half of cancer patients end up with medical debt

By Anastassia Gliadkovskaya

Changes to finances most had to adopt include delaying major purchases, depleting most or all of their savings, going into more credit card debt and borrowing money from relatives and friends.

Newly discovered Alzheimer's biomarkers may bring more equitable screening tests, Mayo Clinic finds

By Andrea Park

The study focused specifically on African-American patients, who are vastly underrepresented in Alzheimer’s research and, on average, have limited access to comprehensive screening resources, but have a disproportionately high risk of developing the disease.

Summit says path forward for failed C. difficile drug is likely through partnerships

By Max Bayer

Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. It hopes to present more data in May. The blueprint from the company comes after its shares have plummeted 50% in the last six months.

PM Tracker